Safety and tolerability of astegolimab, an anti-ST2 monoclonal antibody: a narrative review.

ABSTRACT: Chronic inflammation is an underlying feature of respiratory diseases such as chronic obstructive pulmonary disease (COPD). Novel therapies that target the inflammatory mechanisms driving acute exacerbations of COPD are required. The ST2 receptor, which binds the alarmin interleukin (IL)-33 to initiate an inflammatory response, is a potential target. Astegolimab, a fully human immunoglobulin G2 monoclonal antibody, which binds with high affinity to ST2 to prevent binding of IL-33, is a potential therapy for COPD. However, targeting inflammatory pathways that form part of the immune system may have unintended consequences, such as implications for the response to infection and cardiovascular function. Therefore, an understanding of astegolimab's safety profile in clinical use is essential.

SUBMITTER: Kelsen SG 

PROVIDER: S-EPMC12574037 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature